Today: 21 May 2026
Bitcoin price today: BTC slips toward $87,700 as year-end risk mood drags crypto stocks

Bitcoin price today: BTC slips toward $87,700 as year-end risk mood drags crypto stocks

NEW YORK, December 31, 2025, 17:34 ET — After-hours

  • Bitcoin was down about 0.7% near $87,700 in late U.S. trading, on track for a 2025 loss.
  • U.S. spot bitcoin ETFs logged about $355 million of net inflows on Dec. 30, Farside Investors data showed.
  • Crypto-linked shares including Strategy and Coinbase were lower in after-hours trading.

Bitcoin was down 0.7% at $87,696 on Wednesday, extending a late-year drift that has left the token on track for its first annual loss since 2022.

The year-end slide matters because the market has been treating bitcoin more like a “risk asset” — the kind that often falls when investors cut exposure to stocks and other higher-risk trades. Analysts say that link to equities could tighten further in 2026 as traders focus on interest-rate expectations and valuations in AI-related shares. Investing

U.S. stocks ended the final session of 2025 lower, and trading volumes stayed thin into the New Year holiday, a backdrop that can magnify moves across markets that rely on steady liquidity.

Bitcoin traded between $87,173 and $89,014 on the day, while ether, the second-largest cryptocurrency, was up 0.3% at $2,976.

Crypto-linked U.S. stocks tracked the softer tone after the bell. Strategy was down about 2.3% and Coinbase fell 2.4% in after-hours trading, while miners Marathon Digital slid 3.6% and Riot Platforms eased 0.4%.

The pullback caps a year of sharp swings. Bitcoin surged earlier in 2025 after the election of U.S. President Donald Trump, then fell alongside stocks after tariff headlines, before rebounding to an all-time high above $126,000 in early October.

Days later, the market sold off again after Trump announced a new tariff on Chinese imports and threatened export controls on critical software, Reuters reported. That triggered more than $19 billion of “liquidations” — forced selling when leveraged traders can’t meet margin calls — across crypto positions. Investing

“In 2025, the market showed that bitcoin increasingly exhibits the characteristics of a risk asset,” said Linh Tran, a senior market analyst at XS.com, pointing to a stronger correlation with U.S. equities. Investing

Flows into regulated products offered one of the few bright spots into year-end. U.S. spot bitcoin ETFs — funds that hold bitcoin directly and trade like stocks — posted $355.1 million of net inflows on Dec. 30, snapping a seven-session run of outflows, according to Farside Investors.

BlackRock’s iShares Bitcoin Trust (IBIT) led with $143.7 million, while Ark 21Shares’ ARKB drew $109.6 million and Fidelity’s FBTC took in $78.6 million, the same data showed.

Policy remains a key overhang for 2026. The crypto industry has scored regulatory wins in Washington, including the SEC’s move to dismiss lawsuits against Coinbase and Binance and the passage of a law setting federal rules for dollar-pegged tokens, known as stablecoins, Reuters reported. Investors are still waiting for broader market-structure legislation that could reshape how crypto platforms are regulated.

Traders are watching whether bitcoin can reclaim the $90,000 level as liquidity returns after the holiday break, and whether ETF inflows hold up in early January. A sharp shift in U.S. rates or trade-policy messaging could set the tone, with near-term support seen around Wednesday’s $87,173 low.

Stock Market Today

  • Borsa İstanbul BIST 100 Index Falls Over 6% Amid CHP Party Congress Annulment
    May 21, 2026, 12:37 PM EDT. Borsa İstanbul's BIST 100 Index dropped over 6% following Ankara Regional Court's annulment of the Republican People's Party's (CHP) 38th Ordinary and 21st Extraordinary Congresses, a ruling described as 'absolute nullity'. The banking sector index saw declines exceeding 8%, triggering the market's circuit breaker system, an automatic trade halt to prevent panic selling. Borsa İstanbul temporarily suspended trading on equity and derivatives markets from 17:42 local time; equity trading resumed at 18:01 and derivatives at 18:08, except for warrants and rights. The BIST 100 began the day up 0.20% at 14,040.06 points but slid to 13,899.53 by midday, underscoring investor uncertainty amid political-legal developments.

Latest articles

Ondas Shares Slip After $196.6M AI Defense Contract

Ondas Shares Slip After $196.6M AI Defense Contract

21 May 2026
Ondas shares dropped 3.5% to $9.04 after closing its $196.6 million all-stock acquisition of Israel-based Omnisys. The deal registered 3.1 million shares for resale, raising concerns about increased stock supply. Ondas reported Q1 revenue of $50.1 million, up from $4.3 million a year earlier, but posted a $42.7 million operating loss.
Social Security Payments May Increase in 2027 After Unexpected Inflation Data

Social Security Payments May Increase in 2027 After Unexpected Inflation Data

21 May 2026
The Senior Citizens League raised its 2027 Social Security cost-of-living adjustment forecast to 3.9%, citing higher inflation. That would add about $81 a month to the average retired worker’s check, but the official figure will be set in October. Rising energy, food, and housing costs are driving the estimate. The adjustment would affect over 75 million Social Security and SSI recipients.
Dow Jones Falls as Bond Yields Signal Trouble for Bulls

Dow 50,000 Watch: Oil, Walmart, Nvidia in Focus

21 May 2026
The Dow hovered near 50,000 Thursday as rising oil prices and Treasury yields dampened risk appetite. Brent crude climbed 2.2% to $107.32 a barrel after renewed U.S.-Iran tensions. Walmart shares fell on cautious guidance despite higher sales, while Nvidia’s record results failed to spark a tech rally. The S&P 500 and Nasdaq traded lower in morning action.
Meta stock slips after-hours as scam-ad scrutiny mounts, Manus AI deal draws focus
Previous Story

Meta stock slips after-hours as scam-ad scrutiny mounts, Manus AI deal draws focus

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop